Mersana Therapeutics Return on Equity

Mersana Therapeutics (MRSN) currently reports a ROE of 117.71%. That is above the Healthcare sector average of -75.84%. Use the charts on this page to explore Mersana Therapeutics's ROE history and peer comparisons.

Mersana Therapeutics's ROE of 117.71% is higher than the Healthcare sector average of -75.84%. That is roughly 255.2% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Mersana Therapeutics's current 117.71% should be judged against Healthcare norms (sector average: -75.84%) and against MRSN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 117.71%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.84%. From there, open related valuation or income-statement pages for Mersana Therapeutics, and consider following MRSN for alerts when major investors trade the stock.

Mersana Therapeutics is classified in the Healthcare sector. On ROE, it currently shows 117.71% versus a sector average near -75.84%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MRSN with unrelated industries.